The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy
Open accessAbstract
BACKGROUND: Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous androgen deprivation in a noninferiority randomized trial. METHODS: We enrolled patients with a PSA level greater than 3 ng per milliliter more than 1 year after primary or salvage radiotherapy for localized prostate cancer. Intermittent treatment was provided in 8-month cycles, with nontreatment periods determined according to the PSA level. The primary end point was overall survival. Secondary end points included quality of life, time to castration-resistant disease, and duration of nontreatment intervals. RESULTS: Of 1386 enrolled patients, 690 were randomly assigned to intermittent therapy and 696 to continuous therapy. Median follow-up was 6.9 years. There were no significant between-group differences in adverse events. In the intermittent-therapy group, full testosterone recovery occurred in 35% of patients, and testosterone recovery to the trial-entry threshold occurred in 79%. Intermittent therapy provided potential benefits with respect to physical function, fatigue, urinary problems, hot flashes, libido, and erectile function. There were 268 deaths in the intermittent-therapy group and 256 in the continuous-therapy group. Median overall survival was 8.8 years in the intermittent-therapy group versus 9.1 years in the continuous-therapy group (hazard ratio for death, 1.02; 95% confidence interval, 0.86 to 1.21). The estimated 7-year cumulative rates of disease-related death were 18% and 15% in the two groups, respectively (P=0.24). CONCLUSIONS: Intermittent androgen deprivation was noninferior to continuous therapy with respect to overall survival. Some quality-of-life factors improved with intermittent therapy. (Funded by the Canadian Cancer Society Research Institute and others; ClinicalTrials.gov number, NCT00003653.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,855
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 2,961
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Bolla, M., Van Tienhoven, G., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Billiet, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70223-0 · Cited by 946
Self-citationHorwitz, E. M., Bae, K., Hanks, G. E., Porter, A., Grignon, D. J., Brereton, H. D., Venkatesan, V., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9021 · Cited by 688
Self-citationRoach, M., Bae, K., Speight, J., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C., Valicenti, R., Grignon, D., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649
D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501
Self-citationAkakura, K., Bruchovsky, N., Goldenberg, S. L., Rennie, P. S., Buckley, A. R., & Sullivan, L. D. (1993) · Cancer · doi:10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z · Cited by 373
Self-citationLaverdière, J., Gomez, J., Cusan, L., Raul Suburu, E., Diamond, P., Lemay, M., Candas, B., Fortin, A., & Labrie, F. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00513-5 · Cited by 309
Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.
Bruchovsky, N., Rennie, P. S., Coldman, A. J., Goldenberg, S. L., To, M., & Lawson, D. (1990) · PubMed · Cited by 308
Self-citationGreen, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N., Swanson, C., Watson, R. B., & Gardiner, R. A. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.02917.x · Cited by 239
Sato, N., Gleave, M. E., Bruchovsky, N., Rennie, P. S., Goldenberg, S. L., Lange, P. H., & Sullivan, L. D. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(96)00018-0 · Cited by 184
Self-citationCherrier, M., Rose, A., & Higano, C. (2003) · Journal of Urology · doi:10.1097/01.ju.0000091640.59812.83 · Cited by 149
Self-citationIntermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study
Higano, C. S., Ellis, W., Russell, K., & Lange, P. H. (1996) · Urology · doi:10.1016/s0090-4295(96)00381-0 · Cited by 141
Self-citationIntermittent androgen suppression in the management of prostate cancer
Crook, J. M., Szumacher, E., Malone, S. C., Huan, S. D., & SEGAL, R. J. (1999) · Urology · doi:10.1016/s0090-4295(98)00547-0 · Cited by 114
Self-citationProstate Specific Antigen Recurrence After Definitive Therapy
Freedland, S. J., & Moul, J. W. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.137 · Cited by 91
Higano, C. S., Shields, A. T., Wood, N., Brown, J. E., & Tangen, C. M. (2004) · Urology · doi:10.1016/j.urology.2004.07.019 · Cited by 91
Self-citationStopping Rules for Clinical Trials Incorporating Clinical Opinion
Freedman, L. S., Lowe, D., & Macaskill, P. (1984) · Biometrics · doi:10.2307/2530902 · Cited by 87
Bruchovsky, N., Klotz, L. H., Sadar, M. D., Crook, J. M., Hoffart, D., Godwin, L., Warkentin, M., Gleave, M. E., & Goldenberg, S. L. (2000) · PubMed · Cited by 80
Self-citationOncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
Paparel, P., Cronin, A. M., Savage, C. J., Scardino, P. T., & Eastham, J. A. (2008) · European Urology · doi:10.1016/j.eururo.2008.07.007 · Cited by 71
Oliver, R. T. D., Williams, G., PARIS, A. M. I., & Blandy, J. (1997) · Urology · doi:10.1016/s0090-4295(96)00373-1 · Cited by 67
Spry, N. A., Galvao, D. A., Davies, R., Bianca, S. L., Joseph, D. J., Davidson, A., & Prince, R. L. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08458.x · Cited by 58
Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle, L., Maggio, M., Shahani, S., Braga‐Basaria, M., & Basaria, S. S. (2006) · PubMed · Cited by 53
A pilot study of intermittent androgen deprivation in advanced prostate cancer
Horwich, Huddart, R. A., Gadd, Boyd, Hetherington, Whelan, & Dearnaley (1998) · British Journal of Urology · doi:10.1046/j.1464-410x.1998.00521.x · Cited by 52
Goldenberg, S. L., Me, G., Taylor, D., & Bruchovsky, N. (1999) · PubMed · Cited by 47
Self-citationBody weight, serum cholesterol, and stage of primary breast cancer
Howson, C. P., Kinne, D. W., & Wynder, E. L. (1986) · Cancer · doi:10.1002/1097-0142(19861201)58:11<2546::aid-cncr2820581131>3.0.co;2-n · Cited by 36
Power function arguments in support of an alternative approach for analyzing management trials
Willan, A. R. (1994) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)90058-2 · Cited by 12
Cited by
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815671 · Cited by 930
Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
Nguyen, P. L., Alibhai, S. M. H., Basaria, S., D’Amico, A. V., Kantoff, P. W., Keating, N. L., Penson, D. F., Rosario, D. J., Tombal, B., & Smith, M. R. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.010 · Cited by 831
Metadata
- Authors
- Crook, J. M., O'Callaghan, C. J., Duncan, G., Dearnaley, D. P., Higano, C. S., Horwitz, E. M., Frymire, E., Malone, S., Chin, J., Nabid, A., Warde, P., Corbett, T., Angyalfi, S., Goldenberg, S. L., Gospodarowicz, M. K., Saad, F., Logue, J. P., Hall, E., Schellhammer, P. F., Ding, K., & Klotz, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-09-06
- Volume
- 367
- Issue
- 10
- Pages
- 895-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2107270081
- Cited by
- 499
- References
- 30
- FWCI
- 40.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.